Market Research Logo

Myasthenia Gravis - Market Insight, Epidemiology and Market Forecast 2027

DelveInsight’s ‘Myasthenia Gravis (MG) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of MG in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

 

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Myasthenia Gravis (MG) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

 

Geography Covered

 

The United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2027

 

Myasthenia Gravis (MG) - Disease Understanding and Treatment Algorithm

 

The DelveInsight’s Myasthenia Gravis (MG) market report gives the thorough understanding of the Myasthenia Gravis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Myasthenia Gravis in the US, Europe, and Japan.

 

Myasthenia Gravis Epidemiology

 

The Myasthenia Gravis (MG) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


The disease epidemiology covered in the report provides historical as well as forecasted epidemiology {total prevalent cases, gender-specific cases, severity-specific prevalent cases [Class I, Class II (Class IIa, IIb), Class III (Class IIIa, IIIb), Class IV & Class V], auto-antibodies specific prevalent cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] and diagnosed cases} scenario of Myasthenia Gravis (MG) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.


According to DelveInsight, total prevalent population of Myasthenia Gravis (MG) in 7 major markets was found to be 129, 267 in 2016.

Myasthenia Gravis Drug Chapters

 

This segment of the Myasthenia Gravis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

At present, the therapeutic market size of Myasthenia Gravis is mainly accounted by symptomatic treatments comprising acetylcholinesterase Inhibitors (Mestinon), short-term immunosuppressants (corticosteroids), long-term immunosuppressants (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid acting short-term immunomodulators (intravenous immunoglobulin, plasma exchange), and long-term immunomodulators (thymectomy). Recently, Soliris (Eculizumab) (Alexion Pharmaceuticals) got approval for MG treatment in 2017. This monoclonal antibody (MAB) is used for preventing acetylcholine receptor antibodies from affecting muscle cells and is helpful for patients resistant to the other available therapies, it has significantly impacted the market size of Myasthenia Gravis after its launch. Detailed chapter for upcoming therapies like Rozanolixizumab (UCB Pharma); CFZ533 (Novartis); Efgartigimod (Argenx); RA101495 (Ra Pharmaceuticals); Firdapse (Catalyst Pharmaceuticals); Hizentra (CSL Behring); and IGIV-C (Grifols Therapeutics) have also been covered in the report.

 

Myasthenia Gravis Market Outlook

 

The Myasthenia Gravis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.


This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the market of Myasthenia Gravis in 7MM was found to be USD 2998.1 million in 2016.

 

Myasthenia Gravis Drugs Uptake

 

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Myasthenia Gravis Report Insights

 

Patient Population

Therapeutic Approaches

Pipeline Analysis

Market Size and Trends

Market Opportunities

Impact of upcoming Therapies

Myasthenia Gravis Report Key Strengths

10 Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

Myasthenia Gravis Report Assessment

Current Treatment Practices

Unmet Needs

Detailed Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers

 

Key Benefits

 

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Myasthenia Gravis market

Organize sales and marketing efforts by identifying the best opportunities for Myasthenia Gravis market

 

To understand the future market competition in the Myasthenia Gravis market.

 

Note: We understand the needs of the rapidly changing market and DelveInsight’s is helping the client by providing the most up to date Report. It usually takes 7-10 days to deliver this kind of Report.


Key Insights

1

Myasthenia Gravis Market Overview at a Glance

3

Market Share (%) Distribution of MG in 2017

3

Market Share (%) Distribution of MG in 2027

3

Disease Overview: Myasthenia Gravis

11

Introduction

11

Types of Myasthenia Gravis

13

MGFA Classification of Myasthenia Gravis

17

Etiology

19

Genetic Basis of Myasthenia Gravis

21

Risk Factors

25

Signs and Symptoms

26

Pathophysiology of Myasthenia Gravis

28

Comorbid conditions in MG

33

Diagnosis

35

Epidemiology and Patient Population

41

Key Findings

41

Population and Forecast Parameters

42

7MM Total Prevalent Patient Population of Myasthenia Gravis

43

Country Wise-Epidemiology of Myasthenia Gravis

44

United States

44

Assumptions and Rationale

44

Prevalent cases of Myasthenia Gravis in the United States

46

Gender-specific Prevalent Cases of Myasthenia Gravis in the US

47

Diagnosed cases of Myasthenia Gravis in the US

48

Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in the US

49

Autoantibodies- specific Diagnosed Prevalent cases of Myasthenia Gravis in the US

50

Germany

51

Assumptions and Rationale

51

Prevalent cases of Myasthenia Gravis in Germany

52

Gender-specific Prevalent Cases of Myasthenia Gravis in Germany

53

Diagnosed cases of Myasthenia Gravis in Germany

54

Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Germany

55

Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Germany

56

France

57

Assumptions and Rationale

57

Prevalent cases of Myasthenia Gravis in France

58

Gender-specific Prevalent Cases of Myasthenia Gravis in France

59

Diagnosed cases of Myasthenia Gravis in France

60

Severity-specific Prevalent Cases of Myasthenia Gravis in France

61

Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in France

62

Italy

63

Assumptions and Rationale

63

Prevalent cases of Myasthenia Gravis in Italy

64

Gender-specific Prevalent Cases of Myasthenia Gravis in Italy

65

Diagnosed cases of Myasthenia Gravis in Italy

66

Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Italy

67

Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Italy

68

Spain

69

Assumptions and Rationale

69

Prevalent cases of Myasthenia Gravis in Spain

70

Gender-specific Prevalent Cases of Myasthenia Gravis in Spain

71

Diagnosed cases of Myasthenia Gravis in Spain

72

Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Spain

73

Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Spain

74

United Kingdom

75

Assumptions and Rationale

75

Prevalent cases of Myasthenia Gravis in the United Kingdom

76

Gender-specific Prevalent Cases of Myasthenia Gravis in the United Kingdom

77

Diagnosed cases of Myasthenia Gravis in the United Kingdom

78

Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in the United Kingdom

79

Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in the UK

80

Japan

81

Assumptions and Rationale

81

Prevalent cases of Myasthenia Gravis in Japan

83

Gender-specific Prevalent Cases of Myasthenia Gravis in Japan

84

Diagnosed cases of Myasthenia Gravis in Japan

85

Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Japan

86

Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Japan

87

Current Treatment Practices

88

International Consensus Guidance for Management of Myasthenia Gravis

95

Japanese Clinical Guidelines for Myasthenia Gravis

100

Unmet Needs

104

Marketed drugs

106

Key cross competition- Marketed drugs

106

Soliris: Alexion Pharmaceuticals

107

Drug Description

107

Regulatory Milestones

107

Advantages & Disadvantages

108

Clinical Development

108

Safety and Efficacy

109

Product Profile

110

Mestinon: Valeant Pharmaceuticals

111

Drug Description

111

Regulatory Milestones

111

Advantages & Disadvantages

111

Safety and Efficacy

111

Product Profile

112

Prograf: Astellas Pharma

113

Drug Description

113

Regulatory Milestones

113

Clinical Development

113

Safety and Efficacy

114

Product Profile

117

Venoglobulin IH: Mitsubishi Tanabe Pharma

118

Drug Description

118

Regulatory Milestones

118

Advantages & Disadvantages

118

Clinical Development

119

Product Profile

119

Emerging Therapies

120

Key cross competition- Emerging Therapies

120

Phase-III Drugs

122

Firdapse: Catalyst Pharmaceuticals

122

Product Description

122

Other Development Activities

122

Clinical Development

122

Safety and Efficacy

123

Product Profile

123

Hizentra: CSL Behring

125

Product Description

125

Clinical Development

125

Safety and Efficacy

126

Product Profile

127

IGIV-C: Grifols Therapeutics

129

Product Description

129

Other Development Activities

129

Clinical Development

129

Product Profile

130

Phase-II Drugs

131

Rozanolixizumab: UCB Pharma

131

Product Description

131

Clinical Development

131

Safety and Efficacy

132

Product Profile

132

CFZ533: Novartis

134

Product Description

134

Clinical Development

134

Product Profile

134

Efgartigimod : Argenx

136

Product Description

136

Other Development Activities

136

Clinical Development

137

Safety and Efficacy

137

Product Profile

138

RA101495: Ra Pharmaceuticals

139

Product Description

139

Other Development Activities

139

Clinical Development

139

Safety and Efficacy

140

Product Profile

140

Myasthenia Gravis: 7 Major Market Analysis

142

Key Findings

142

Market Size of Myasthenia Gravis in 7MM

143

Market Outlook by Country

144

The United States: Market Outlook

144

United States Market Size

148

Total Market size of Myasthenia Gravis

148

Market Size of Myasthenia Gravis by Current Therapies

149

Market Size of Myasthenia Gravis by Emerging Therapies

150

EU-5 Countries: Market Outlook

151

Germany

152

Total Market size of Myasthenia Gravis

152

Market Size of Myasthenia Gravis by Current Therapies

153

Market Size of Myasthenia Gravis by Emerging Therapies

154

France

155

Total Market size of Myasthenia Gravis

155

Market Size of Myasthenia Gravis by Current Therapies

156

Market Size of Myasthenia Gravis by Emerging Therapies

157

Italy

158

Total Market size of Myasthenia Gravis

158

Market Size of Myasthenia Gravis by Current Therapies

159

Market Size of Myasthenia Gravis by Emerging Therapies

160

Spain

161

Total Market size of Myasthenia Gravis

161

Market Size of Myasthenia Gravis by Current Therapies

162

Market Size of Myasthenia Gravis by Emerging Therapies

163

United Kingdom

164

Total Market size of Myasthenia Gravis

164

Market Size of Myasthenia Gravis by Current Therapies

165

Market Size of Myasthenia Gravis by Emerging Therapies

166

Japan: Market Outlook

167

Total Market size of Myasthenia Gravis

169

Market Size of Myasthenia Gravis by Current Therapies

170

Market Size of Myasthenia Gravis by Emerging Therapies

171

Market Drivers

172

Market Barriers

173

Appendix

174

Report Methodology

174

DelveInsight Capabilities

176

Disclaimer

177

About DelveInsight

177

 

 

 

 




List of Tables

Table 1: Osserman & Genkins Classification of Myasthenia Gravis, modified by the MGFA/Task Force

17

Table 2: Prevalent Patient Population of Myasthenia Gravis in 7MM (2016-2027)

43

Table 3: Prevalent Cases of Myasthenia Gravis in the United States (2016-2027)

46

Table 4: Gender-specific Prevalent Cases of Myasthenia Gravis in the United States (2016-2027)

47

Table 5: Diagnosed cases of Myasthenia Gravis in the United States (2016-2027)

48

Table 6: Severity-specific  Diagnosed Prevalent Cases of Myasthenia Gravis in the US (2016-2027)

49

Table 7: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in the US (2016-2027)

50

Table 8: Prevalent Cases of Myasthenia Gravis in Germany (2016-2027)

52

Table 9: Gender-specific Prevalent Cases of Myasthenia Gravis in Germany (2016-2027)

53

Table 10: Diagnosed Cases of Myasthenia Gravis in Germany (2016-2027)

54

Table 11: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in Germany (2016-2027)

55

Table 12: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Germany (2016-2027)

56

Table 13: Prevalent Cases of Myasthenia Gravis in France (2016-2027)

58

Table 14: Gender-specific Prevalent Cases of Myasthenia Gravis in France (2016-2027)

59

Table 15: Diagnosed cases of Myasthenia Gravis in France (2016-2027)

60

Table 16: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in France (2016-2027)

61

Table 17: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in France (2016-2027)

62

Table 18: Prevalent Cases of Myasthenia Gravis in Italy (2016-2027)

64

Table 19: Gender-specific Prevalent Cases of Myasthenia Gravis in Italy (2016-2027)

65

Table 20: Diagnosed cases of Myasthenia Gravis in Italy (2016-2027)

66

Table 21: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in Italy (2016-2027)

67

Table 22: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Italy (2016-2027)

68

Table 23: Prevalent Cases of Myasthenia Gravis in Spain (2016-2027)

70

Table 24: Gender-specific Prevalent Cases of Myasthenia Gravis in Spain (2016-2027)

71

Table 25: Diagnosed cases of Myasthenia Gravis in Spain (2016-2027)

72

Table 26: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in Spain (2016-2027)

73

Table 27: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Spain (2016-2027)

74

Table 28: Prevalent Cases of Myasthenia Gravis in the United Kingdom (2016-2027)

76

Table 29: Gender-specific Prevalent Cases of Myasthenia Gravis in the United Kingdom (2016-2027)

77

Table 30: Diagnosed cases of Myasthenia Gravis in the United Kingdom (2016-2027)

78

Table 31: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in the UK (2016-2027)

79

Table 32: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in the UK (2016-2027)

80

Table 33: Prevalent Cases of Myasthenia Gravis in Japan (2016-2027)

83

Table 34: Gender-specific Prevalent Cases of Myasthenia Gravis in Japan (2016-2027)

84

Table 35: Diagnosed Cases of Myasthenia Gravis in Japan (2016-2027)

85

Table 36: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in Japan (2016-2027)

86

Table 37: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Japan (2016-2027)

87

Table 38: Japanese Clinical Guidelines for Myasthenia Gravis

100

Table 39: Japanese Treatment Strategies for Myasthenia Gravis

102

Table 40: Key cross competition- Marketed drugs

106

Table 41: Eculizumab, Clinical Trial Description, 2018

108

Table 42: Tacrolimus, Clinical Trial Description, 2018

114

Table 43: GB-0998, Clinical Trial Description, 2018

119

Table 44: Key cross competition - Emerging Therapies

120

Table 45: Amifampridine Phosphate, Clinical Trial Description, 2018

123

Table 46: Hizentra, Clinical Trial Description, 2018

125

Table 47: IGIV-C, Clinical Trial Description, 2018

130

Table 48: UCB7665, Clinical Trial Description, 2018

131

Table 49: CFZ533, Clinical Trial Description, 2018

134

Table 50: Efgartigimod, Clinical Trial Description, 2018

137

Table 51: RA101495, Clinical Trial Description, 2018

140

Table 52: 7 Major Market Size of Myasthenia Gravis in USD Million (2016-2027)

143

Table 53: United States Market Size of Myasthenia Gravis in USD Million (2016-2027)

148

Table 54:  Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

149

Table 55: US Myasthenia Gravis Market size by Emerging Therapies in USD Million (2016-2027)

150

Table 56: Germany Market Size of Myasthenia Gravis in USD Million (2016-2027)

152

Table 57:  Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

153

Table 58: Germany Myasthenia Gravis Market size by Emerging Therapies in USD Million (2016-2027)

154

Table 59: France Market Size of Myasthenia Gravis in USD Million (2016-2027)

155

Table 60:  Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

156

Table 61: France Myasthenia Gravis Market size by Emerging Therapies in USD Million (2016-2027)

157

Table 62: Italy Market Size of Myasthenia Gravis in USD Million (2016-2027)

158

Table 63:  Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

159

Table 64: Italy Myasthenia Gravis Market size by Emerging Therapies in USD Million (2016-2027)

160

Table 65: Spain Market Size of Myasthenia Gravis in USD Million (2016-2027)

161

Table 66:  Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

162

Table 67: Spain Myasthenia Gravis Market size by Emerging Therapies in USD Million (2016-2027)

163

Table 68: United Kingdom Market Size of Myasthenia Gravis in USD Million (2016-2027)

164

Table 69:  Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

165

Table 70: UK Myasthenia Gravis Market size by Emerging Therapies in USD Million (2016-2027)

166

Table 71: Japan Market Size of Myasthenia Gravis in USD Million (2016-2027)

169

Table 72:  Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

170

Table 73: Japan Myasthenia Gravis Market size by Emerging Therapies in USD Million (2016-2027)

171

 

 


 

List of Figures

Figure 1: Transmission of Nerve Impulses to Muscles

15

Figure 2: Signs and Symptoms of Myasthenia Gravis

27

Figure 3: Various Components of the Neuromuscular Junction involved in MG

30

Figure 4: Diagnostic testing in myasthenia gravis

38

Figure 5: Diagnosis flowchart for MG

39

Figure 6: Prevalent Patient Population of Myasthenia Gravis in 7MM (2016-2027)

43

Figure 7: Prevalent Cases of Myasthenia Gravis in the United States (2016-2027)

46

Figure 8: Gender-specific Prevalent Cases of Myasthenia Gravis in the United States (2016-2027)

47

Figure 9: Diagnosed cases of Myasthenia Gravis in the United States (2016-2027)

48

Figure 10: Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in the US (2016-2027)

49

Figure 11: Autoantibodies-specific Diagnosed Prevalent cases of Myasthenia Gravis in the US (2016-2027)

50

Figure 12: Prevalent Cases of Myasthenia Gravis in Germany (2016-2027)

52

Figure 13: Gender-specific Prevalent Cases of Myasthenia Gravis in Germany (2016-2027)

53

Figure 14: Diagnosed cases of Myasthenia Gravis in Germany (2016-2027)

54

Figure 15: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in Germany (2016-2027)

55

Figure 16: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Germany (2016-2027)

56

Figure 17: Prevalent Cases of Myasthenia Gravis in France (2016-2027)

58

Figure 18: Gender-specific Prevalent Cases of Myasthenia Gravis in France (2016-2027)

59

Figure 19: Diagnosed cases of Myasthenia Gravis in France (2016-2027)

60

Figure 20: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in France (2016-2027)

61

Figure 21: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in France (2016-2027)

62

Figure 22: Prevalent Cases of Myasthenia Gravis in Italy (2016-2027)

64

Figure 23: Gender-specific Prevalent Cases of Myasthenia Gravis in Italy (2016-2027)

65

Figure 24: Diagnosed cases of Myasthenia Gravis in Italy (2016-2027)

66

Figure 25: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in Italy (2016-2027)

67

Figure 26: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Italy (2016-2027)

68

Figure 27: Prevalent Cases of Myasthenia Gravis in Spain (2016-2027)

70

Figure 28: Gender-specific Prevalent Cases of Myasthenia Gravis in Spain (2016-2027)

71

Figure 29: Diagnosed cases of Myasthenia Gravis in Spain (2016-2027)

72

Figure 30: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in Spain (2016-2027)

73

Figure 31: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Spain (2016-2027)

74

Figure 32: Prevalent Cases of Myasthenia Gravis in the United Kingdom (2016-2027)

76

Figure 33: Gender-specific Prevalent Cases of Myasthenia Gravis in the United Kingdom (2016-2027)

77

Figure 34: Diagnosed cases of Myasthenia Gravis in the United Kingdom (2016-2027)

78

Figure 35: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in the UK (2016-2027)

79

Figure 36: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in the UK (2016-2027)

80

Figure 37: Prevalent Cases of Myasthenia Gravis in Japan (2016-2027)

83

Figure 38: Gender-specific Prevalent Cases of Myasthenia Gravis in Japan (2016-2027)

84

Figure 39: Diagnosed cases of Myasthenia Gravis in Japan (2016-2027)

85

Figure 40: Severity specific Diagnosed Prevalent Cases of Myasthenia Gravis in Japan (2016-2027)

86

Figure 41: Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Japan (2016-2027)

87

Figure 42: Treatment of Generalized Myasthenia Gravis

92

Figure 43: Treatment of Severe Myasthenia Gravis Exacerbations

94

Figure 44: Unmet Needs for Myasthenia Gravis

104

Figure 45: 7 Major Market Size of Myasthenia Gravis in USD Million (2016-2027)

143

Figure 46: Market Size of Myasthenia Gravis in the United States, USD Millions (2016-2027)

148

Figure 47: Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

149

Figure 48: US Myasthenia Gravis Market size by Emerging Therapies in USD Million (2016-2027)

150

Figure 49: Market Size of Myasthenia Gravis in Germany, USD Millions (2016-2027)

152

Figure 50: Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

153

Figure 51: Germany MG Market by Emerging Therapies in USD Million (2016-2027)

154

Figure 52: Market Size of Myasthenia Gravis in France USD Millions (2016-2027)

155

Figure 53: Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

156

Figure 54: France Myasthenia Gravis Market by Emerging Therapies in USD Million (2016-2027)

157

Figure 55: Market Size of Myasthenia Gravis in Italy, USD Millions (2016-2027)

158

Figure 56: Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

159

Figure 57: Italy Myasthenia Gravis Market by Emerging Therapies in USD Million (2016-2027)

160

Figure 58: Market Size of Myasthenia Gravis in Spain, USD Millions (2016-2027)

161

Figure 59: Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

162

Figure 60: Spain Myasthenia Gravis Market by Emerging Therapies in USD Million (2016-2027)

163

Figure 61: Market Size of Myasthenia Gravis in the United Kingdom, USD Millions (2016-2027)

164

Figure 62: Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

165

Figure 63: UK Myasthenia Gravis Market by Emerging Therapies in USD Million (2016-2027)

166

Figure 64: Market Size of Myasthenia Gravis in Japan, USD Millions (2016-2027)

169

Figure 65: Market Size of Myasthenia Gravis by Current Therapies in USD Million (2016-2027)

170

Figure 66: Japan Myasthenia Gravis Market by Emerging Therapies in USD Million (2016-2027)

171

Figure 67: Market Drivers

172

Figure 68:Market Barriers

173

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report